The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+ Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer

Overview

Journal Oncology

Specialty Oncology

Date 2021 Jun 9

PMID 34107469

Citations 1

Authors

Jinsoo Lee

Yoon Yang Jung

Jung Hoon Lee

Mineui Hong

Hye-Won Hwang

Soon Auck Hong

Sook-Hee Hong

Affiliations

Soon will be listed here.

Abstract

Background: Sex-determining region Y-box 2 (SOX2) is a transcriptional factor that drives embryonic stem cells to neuroendocrine cells in lung development and is highly expressed in small-cell lung cancer (SCLC). However, the prognostic role of SOX2 and its relationship with tumor-infiltrating lymphocytes (TILs) has not been determined in SCLC. Herein, we assessed the expression of SOX2 and CD8+ TILs to obtain insights into the prognostic role of SOX2 and CD8+ TILs in limited-stage (LS)-SCLC.

Methods: A total of 75 patients with LS-SCLC was enrolled. The SOX2 expression and CD8+ TILs were evaluated by immunohistochemistry.

Results: High SOX2 and CD8+ TIL levels were identified in 52 (69.3%) and 40 (53.3%) patients, respectively. High SOX2 expression was correlated with increased density of CD8+ TILs (p = 0.041). Unlike SOX2, high CD8+ TIL numbers were associated with significantly longer progression-free survival (PFS; 13.9 vs. 8.0 months, p = 0.014). Patients with both high SOX2 expression and CD8+ TIL numbers (n = 29, 38.7%) had significantly longer PFS and overall survival (OS) compared to those from the other groups (median PFS 19.3 vs. 8.4 months; p = 0.002 and median OS 35.7 vs. 17.4 months; p = 0.004, respectively). Multivariate Cox regression analysis showed that the combination of high SOX2 expression and CD8+ TIL levels was an independent good prognostic factor for OS (HR = 0.471, 95% CI, 0.250-0.887, p = 0.02) and PFS (HR = 0.447, 95% CI, 0.250-0.801, p = 0.007) in SCLC.

Conclusions: Evaluation of the combination of SOX2 and CD8+ TIL levels may be of a prognostic value in LS-SCLC.

Citing Articles

Tumor Microenvironment in Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: Interaction between Tumors and Immune Cells, and Potential Effects of Neuroendocrine Differentiation on the Tumor Microenvironment.

Tsunokake J, Fujishima F, Watanabe H, Sato I, Miura K, Sakamoto K Cancers (Basel). 2022; 14(9).

PMID: 35565281 PMC: 9100554. DOI: 10.3390/cancers14092152.

References

Warde P, Payne D . Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992; 10(6):890-5. DOI: 10.1200/JCO.1992.10.6.890. View

Iams W, Shiuan E, Meador C, Roth M, Bordeaux J, Vaupel C . Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes. J Thorac Oncol. 2019; 14(11):1970-1981. PMC: 6823126. DOI: 10.1016/j.jtho.2019.05.042. View

Chen P, Zhang L, Zhang W, Sun C, Wu C, He Y . Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer. J Immunother Cancer. 2020; 8(2). PMC: 7577067. DOI: 10.1136/jitc-2020-001391. View

Sun Y, Zhang R, Wang M, Zhang Y, Qi J, Li J . SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2012; 21(11):2043-7. DOI: 10.1158/1055-9965.EPI-12-0498. View

Albert M, Darnell R . Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer. 2004; 4(1):36-44. DOI: 10.1038/nrc1255. View

McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9. PMC: 4984254. DOI: 10.1126/science.aaf1490. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Titulaer M, Klooster R, Potman M, Sabater L, Graus F, Hegeman I . SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009; 27(26):4260-7. DOI: 10.1200/JCO.2008.20.6169. View

Sabari J, Lok B, Laird J, Poirier J, Rudin C . Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017; 14(9):549-561. PMC: 5843484. DOI: 10.1038/nrclinonc.2017.71. View

10.

Dhodapkar K, Gettinger S, Das R, Zebroski H, Dhodapkar M . SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology. 2013; 2(7):e25205. PMC: 3782159. DOI: 10.4161/onci.25205. View

11.

Zhang S, Cui W . Sox2, a key factor in the regulation of pluripotency and neural differentiation. World J Stem Cells. 2014; 6(3):305-11. PMC: 4131272. DOI: 10.4252/wjsc.v6.i3.305. View

12.

Daly M, Ismaila N, Decker R, Higgins K, Owen D, Saxena A . Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline. J Clin Oncol. 2021; 39(8):931-939. DOI: 10.1200/JCO.20.03364. View

13.

Kalemkerian G, Schneider B . Advances in Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2016; 31(1):143-156. DOI: 10.1016/j.hoc.2016.08.005. View

14.

Hong S, Hwang H, Kim M, Lee T, Yim K, Won H . High Endothelial Venule with Concomitant High CD8+ Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer. J Clin Med. 2020; 9(8). PMC: 7464373. DOI: 10.3390/jcm9082628. View

15.

Vallieres E, Shepherd F, Crowley J, Van Houtte P, Postmus P, Carney D . The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4(9):1049-59. DOI: 10.1097/JTO.0b013e3181b27799. View

16.

Zhang X, Zhang Y, Xu J, Wang H, Zheng X, Lou Y . Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells. J Cancer. 2018; 9(2):367-374. PMC: 5771344. DOI: 10.7150/jca.20821. View

17.

Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S . Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer. Onco Targets Ther. 2020; 13:6475-6483. PMC: 7342461. DOI: 10.2147/OTT.S252031. View

18.

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

19.

Nicholson A, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A . The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung.... J Thorac Oncol. 2016; 11(3):300-11. DOI: 10.1016/j.jtho.2015.10.008. View

20.

Yang F, Gao Y, Geng J, Qu D, Han Q, Qi J . Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol. 2013; 6(12):2846-54. PMC: 3843264. View